Application 18/635,580
Final mailedSubstituted imidazolidin-2-one derivatives as prmt5 inhibitors
Art unit 3991·Examiner Diamond, Alan D·Filed Apr 15, 2024·Status since Jul 23, 2026
Applicant Aurigene Discovery Technologies Limited·Inventor Dinesh CHIKKANNA et al.
Analysis as of Aug 11, 2026
It covers the Office Actions on file on that date and is not updated. The status above is current.
The latest Office Action
Mailed Jul 23, 2026 · Final Office Action
14 days to respond: the shortened statutory period ends Oct 23, 2026.
The examiner issued a Final Office Action addressing a double patenting rejection over US11365205. No substantive rejections under §101, §102, or §103 remain. The examiner has indicated that claims 4, 7-9 contain allowable subject matter but need formal corrections before they can be allowed.
The applicant has three months (extendable to six) to respond. Common next steps include filing a terminal disclaimer to overcome the double patenting rejection and correcting the objected claims per the examiner's guidance. Once these formalities are addressed, the claims should be in condition for allowance. An attorney typically handles this; if you'd like patentreply.ai to draft a response, click 'Get this drafted'.
Claim status
- Objected4 claims4, 7-9